How much will Pertuzumab cost in 2023?

Pertuzumab (Pertuzumab) is a recombinant humanized monoclonal antibody that binds to the extracellular dimerization domain II of HER2. It was recently approved for adjuvant and neoadjuvant treatment of HER2-positive early breast cancer. Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is a unique subtype of breast cancer caused by overexpression of the HER2 protein.

Because pertuzumab and trastuzumab bind to different domains of the extracellular dimerization domain of HER2, combination therapy with pertuzumab and trastuzumab is beneficial for the treatment of metastatic cancers, advanced localized cancers, or early-stage cancers through dual HER2 blockade. In multiple clinical studies, pertuzumab was a safe and effective drug regardless of patient age and hormone receptor status. Of note, the use of pertuzumab has been associated with severe cardiotoxicity in some cases; however, the risk of cardiac dysfunction with pertuzumab is low and the most common adverse reaction associated with the use of pertuzumab is diarrhea, but most cases are not severe.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.